Connor, Clark & Lunn Investment Management Ltd. I Mab Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in I Mab stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 27,800 shares of IMAB stock, worth $145,116. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,800Holding current value
$145,116% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding IMAB
# of Institutions
40Shares Held
15.8MCall Options Held
10.2KPut Options Held
0-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$31.2 Million0.6% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$21.8 Million3.04% of portfolio
-
Ariose Capital Management LTD Central, Hong Kong, K31.7MShares$8.9 Million2.68% of portfolio
-
Candriam S.C.A.1.13MShares$5.91 Million0.02% of portfolio
-
Sg Americas Securities, LLC876KShares$4.57 Million0.01% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $434M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...